|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Isoflavones’effects on pharmacokinetic profiles of main iridoids from Gardeniae Fructus in rats显示文摘Gardeniae Fructus(GF)and Semen Sojae Praeparatum(SSP)are both medicine food homologies and widely used in Chinese clinical prescriptions together.The research investigated the pharmacokinetics of four iridoids in normal rats and isolfavones-fed rats,which were administered with isolfavones from SSP for 7,14,21 and 28 consecutive days.A validated LC-MS/MS method was developed for determining shanzhiside,genipin-1-gentiobioside,geniposide and their metabolite genipin in rat plasma.Plasma samples were pretreated by solid-phase extraction using paeoniflorin as the internal standard.The chromatographic separation was performed on a Waters Atlantis T3(4.6 mm×150 mm,3 mm)column using a gradient mobile phase consisting of acetonitril and water(containing 0.06%acetic acid).The mass detection was under the multiple reaction monitoring(MRM)mode via polarity switching between negative and positive ionization modes.The calibration curves exhibited good linearity(r>0.997)for all components.The lower limit of quantitation was in the range of 1 e10 ng/m L.The intra-day and inter-day precisions(RSD)at three different levels were both less than 12.2%and the accuracies(RE)ranged fromà10.1%to 16.4%.The extraction recovery of them ranged from 53.8%to 99.7%.Pharmacokinetic results indicated the bioavailability of three iridoid glycosides and the metabolite,genipin in normal rats was higher than that in rats exposed to isoflavones.With the longer time of administration of isoflavones,plasma concentrations of iridoids decreased,while genipin sulfate,the phase II metabolite of genposide and genipin-1-gentiobioside,appeared the rising exposure.The pharmacokinetic profiles of main iridoids from GF were altered by isoflavones. | Ruirui Chang Jialin Liu Yusha Luo Taohong Huang Qiang Li Jun Wen Weidong Chen Tingting Zhou | 2020 | Journal of Pharmaceutical Analysis2020，10，6： | 2 |
| 2 | Cell-delivery therapeutics for liver regeneration显示文摘 | Wenxia Zhang Lisa Tucker-Kellogg B.C. Narmada Lakshmi Venkatraman Shi Chang Yin Lu Nancy Tan Jacob K. White Ruirui Jia Sourav Saha Bhowmick Shali Shen C. Forbes Dewey Hanry Yu | 2010 | Advanced Drug Delivery Reviews2010，，7： | 1 |
| 3 | Targeting UHRF1-SAP30-MXD4 axis for leukemia initiating cell eradication in myeloid leukemia显示文摘Aberrant self-renewal of leukemia initiation cells(LICs)drives aggressive acute myeloid leukemia(AML).Here,we report that UHRF1,an epigenetic regulator that recruits DNMT1 to methylate DNA,is highly expressed in AML and predicts poor prognosis.UHRF1 is required for myeloid leukemogenesis by maintaining self-renewal of LICs.Mechanistically,UHRF1 directly interacts with Sin3A-associated protein 30(SAP30)through two critical amino acids,G572 and F573 in its SRA domain,to repress gene expression.Depletion of UHRF1 or SAP30 derepresses an important target gene,MXD4,which encodes a MYC antagonist,and leads to suppression of leukemogenesis.Further knockdown of MXD4 can rescue the leukemogenesis by activating the MYC pathway.Lastly,we identified a UHRF1 inhibitor,UF146,and demonstrated its significant therapeutic efficacy in the myeloid leukemia PDX model.Taken together,our study reveals the mechanisms for altered epigenetic programs in AML and provides a promising targeted therapeutic strategy against AML. | Cheng-Long Hu Bing-Yi Chen Zijuan Li Tianbiao Yang Chun-Hui Xu Ruirui Yang Peng-Cheng Yu Jingyao Zhao Ting Liu Na Liu Bin Shan Qunling Zhang Junhong Song Ming-Yue Fei Li-Juan Zong Jia-Ying Zhang Ji-Chuan Wu Shu-Bei Chen Yong Wang Binhe Chang Dan Hou Ping Liu Yilun Jiang Xiya Li Xinchi Chen Chu-Han Deng Yi-Yi Ren Roujia Wang Jiacheng Jin Kai Xue Ying Zhang Meirong Du Jun Shi Ling-Yun Wu Chun-Kang Chang Shuhong Shen Zhu Chen Sai-Juan Chen Xiaolong Liu Xiao-Jian Sun Mingyue Zheng Lan Wang | 2022 | Cell Research2022，32，12： | 1 |
| 4 | Discovery of ARF1-targeting inhibitor demethylzeylasteral as a potential agent against breast cancer显示文摘To the Editor:ADP-ribosylation factor 1 (ARF1) plays a critical role in regulating vesicle formation and transport1. The dysregulation of ARF1 expression and/or activity is involved in many human cancers, such as breast cancer2,3. Therefore, ARF1 is one of the promising therapeutic targets for cancer treatment. | Jie Chang Ruirui Yang Lifan Chen Zisheng Fan Jingyi Zhou Hao Guo Yinghui Zhang Yadan Liu Guizhen Zhou Keke Zhang Kaixian Chen Hualiang Jiang Mingyue Zheng Sulin Zhang | 2022 | Acta Pharmaceutica Sinica B2022，12，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员